Phase 2 N=121 Modulation of Immune Activation by Aspirin
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
HIV Infections
Primary: Symptom Score — 10; 8 units on a scale — p=0.45
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 2 N=76 Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
HIV-1 Infection
Primary: Change in CD8+ T-cell Activation From Baseline to Week 14/16 — 3.24; 0.52 percentage of cells — p=0.030
Phase 4 N=56 Mechanisms of Lipodystrophy in HIV-Infected Pateints
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
Phase 2 N=40 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
Kaposi Sarcoma · Human Immunodeficiency Virus · Immune Reconstitution Syndrome
Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants
N/A N=100 Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms
HIV (Human Immunodeficiency Virus) · AIDS (Acquired Immunodeficiency Syndrome)
Primary: Symptom Burden Score — 1.08; 1.06; 0.83; 0.71 score on a scale — p=0.02
Phase 4 N=70 Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)
HIV · Tuberculosis
Primary: Number of Serious Adverse Events (SAEs) — 12; 7 Events
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
Phase 2 N=10 MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Severe Combined Immunodeficiency
Primary: Number of Participants With Adverse Events — 10; 9; 0; 10 participants
Phase 3 N=192 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
HIV-1 Infection · Kaposi's Sarcoma
Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911
N/A N=223 Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences
HIV Infections
Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
N/A N=328 Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
HIV Infection
Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013
Phase 3 N=4,150 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
HIV Infections
Primary: New or Recurrent HIV Disease Progression Event Including Death — 159; 165 participants — p=.55
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
N/A N=175 Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
HIV Infection · Human Immunodeficiency Virus 1 Positive · Malignant Neoplasm
Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…
Phase 2 N=68 Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
HIV-1
Primary: Percentage of Participants With Clonal Expansion of Cells With a Predominant OZ1 Insertion Site — 0 Percentage of participants
Phase 4 N=1,771 Antiretroviral Therapy for Advanced HIV Disease in South Africa
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
N/A N=10 Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
Hepatitis C
Primary: Number of Participants Who Completed Standard Treatment — 10; 0 participants
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
N/A N=13 Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
HIV Infection
Primary: Time to Meeting Criteria for ART Re-initiation — 17.1; 10.1; 13.3 Weeks
Phase 3 N=8,657 Evaluation of Diagnostic HIV Ag/Ab Combo Assay
Human Immunodeficiency Viruses
Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens
Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
N/A N=18 Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study
HIV Infection
Primary: Time to Meeting Criteria for ART Re-initiation — 7.9; 8.9; 7.6 Weeks
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
N/A N=10 Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
AIDS-Related Kaposi Sarcoma · Human Immunodeficiency Virus 1 Positive
Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale
Phase 1 N=15 Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
HIV-1 Infection
Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 0 percentage of participants
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants